As the overall uptake of [177Lu]Lu-PSMA-617 appears to be transporter-independent, both the abundance of vital transporters and its age-dependent decrease should not interfere with the delivery of PSMA-based radioligands to tumor cells, enabling a positive treatment outlook for all patients. The gene discussed is FOLH1; the disease is neoplasm.